文献速递细菌感染、耐药与抗菌药物

界定欧洲兽医抗微生物药物耐药性监测网络(EARS-Vet)的范围:一种自下而上的同一健康方法

Defining the scope of the European Antimicrobial Resistance Surveillance network in Veterinary medicine (EARS-Vet): a bottom-up and One Health approach.
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

为强化欧洲同一健康抗微生物药物耐药性(AMR)监测,26位欧洲专家通过共识确定了EARS-Vet的监测范围,涵盖6种动物、11种细菌及相应抗菌药物,并计划收集ESBLs、AmpC头孢菌素酶和甲氧西林耐药分子数据。该初步范围有望填补欧洲动物领域AMR监测的重要空白。

要点

  • EARS-Vet计划监测6种动物(牛、猪、鸡、火鸡、猫、狗)的AMR。
  • 监测11种细菌,包括大肠埃希菌、肺炎克雷伯菌、金黄色葡萄球菌等。
  • 选择治疗相关抗菌药物(如四环素类)并补充公共卫生相关药物(如碳青霉烯类)。

核心结论

  • 初步确定了EARS-Vet范围,有望填补欧洲动物领域AMR监测的重要空白。
  • 该范围应随AMR流行病学变化、更多国家参与和国家监测能力提升而审查和扩展。

研究设计与样本

  • 通过26位欧洲专家的共识确定EARS-Vet范围。
  • 决策依据包括对13个欧洲国家患病动物相关且可行监测组合的调查(自下而上方法)。
  • 专家还考虑了同一健康方法及EARS-Vet补充ECDC和EFSA协调的现有欧洲AMR监测系统的需求。

主要发现

  • EARS-Vet计划监测6种动物:牛、猪、鸡(肉鸡和蛋鸡)、火鸡、猫和狗。
  • 计划监测11种细菌:大肠埃希菌、肺炎克雷伯菌、溶血性曼氏杆菌、多杀性巴氏杆菌、胸膜肺炎放线杆菌、金黄色葡萄球菌、假中间葡萄球菌、猪葡萄球菌、乳房链球菌、停乳链球菌和猪链球菌。
  • 选择了治疗相关抗菌药物(如四环素类),并补充了更具特定公共卫生意义的抗菌药物(如碳青霉烯类)。
  • 还将收集检测ESBLs、AmpC头孢菌素酶和甲氧西林耐药存在的分子数据。

局限性

  • 该范围为初步界定,应随AMR流行病学变化、更多国家参与和国家监测能力提升而审查和扩展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Building the European Antimicrobial Resistance Surveillance network in Veterinary medicine (EARS-Vet) was proposed to strengthen the European One Health antimicrobial resistance (AMR) surveillance approach. OBJECTIVES: To define the combinations of animal species/production types/age categories/bacterial species/specimens/antimicrobials to be monitored in EARS-Vet. METHODS: The EARS-Vet scope was defined by consensus between 26 European experts. Decisions were guided by a survey of the combinations that are relevant and feasible to monitor in diseased animals in 13 European countries (bottom-up approach). Experts also considered the One Health approach and the need for EARS-Vet to complement existing European AMR monitoring systems coordinated by the ECDC and the European Food Safety Authority (EFSA). RESULTS: EARS-Vet plans to monitor AMR in six animal species [cattle, swine, chickens (broilers and laying hens), turkeys, cats and dogs], for 11 bacterial species (Escherichia coli, Klebsiella pneumoniae, Mannheimia haemolytica, Pasteurella multocida, Actinobacillus pleuropneumoniae, Staphylococcus aureus, Staphylococcus pseudintermedius, Staphylococcus hyicus, Streptococcus uberis, Streptococcus dysgalactiae and Streptococcus suis). Relevant antimicrobials for their treatment were selected (e.g. tetracyclines) and complemented with antimicrobials of more specific public health interest (e.g. carbapenems). Molecular data detecting the presence of ESBLs, AmpC cephalosporinases and methicillin resistance shall be collected too. CONCLUSIONS: A preliminary EARS-Vet scope was defined, with the potential to fill important AMR monitoring gaps in the animal sector in Europe. It should be reviewed and expanded as the epidemiology of AMR changes, more countries participate and national monitoring capacities improve.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Mader R, Bourély C, Amat JP, et al. Defining the scope of the European Antimicrobial Resistance Surveillance network in Veterinary medicine (EARS-Vet): a bottom-up and One Health approach. J Antimicrob Chemother. 2022. PMID: 35022739. doi:10.1093/jac/dkab462

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。